Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
Real-time Estimate Cboe Europe  -  07:17 2022-08-12 am EDT
314.43 CHF   +1.38%
04:47aEuropean shares rise as healthcare rebounds, travel stocks gain
RE
01:00aRoche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older
AQ
01:00aRoche Announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ROCHE HOLDINGS AG : JP Morgan reiterates its Neutral rating

05/27/2022 | 05:47am EDT
share with twitter
share with LinkedIn
share with facebook

In his latest research note, analyst Richard Vosser confirms his recommendation. The broker JP Morgan is keeping its Neutral rating. The target price is still set at CHF 370.


© MarketScreener with dpa-AFX Analyser 2022
All news about ROCHE HOLDING AG
04:47aEuropean shares rise as healthcare rebounds, travel stocks gain
RE
01:00aRoche announces U.S. FDA approval of Xofluza to treat influenza in children aged five y..
AQ
01:00aRoche Announces U.S. FDA approval of Xofluza to treat influenza in children aged five y..
CI
08/11Roche's Genentech Gets US FDA Nod For Influenza Drug In Children Aged Five To 12
MT
08/11Genentech Announces FDA Approval of Xofluza to Treat Influenza in Children Aged Five an..
BU
08/11GENENTECH : FDA Approves Xofluza to Treat Influenza in Children Aged 5 and Older
DJ
08/11GLOBAL MARKETS LIVE : Walt Disney, Bank of America, Sonos, ABB, Roche...
MS
08/11Chugai Pharmaceutical Co., Ltd. - Anti-C5 Recycling Antibody Crovalimab Obtains Priorit..
AQ
08/11ROCHE HOLDINGS AG : Deutsche Bank reiterates its Neutral rating
MD
08/11Roche Obtains US FDA Approval For Expansion Of Ventana Diagnostic Test
MT
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2022 64 190 M 68 260 M 68 260 M
Net income 2022 14 826 M 15 766 M 15 766 M
Net Debt 2022 10 272 M 10 923 M 10 923 M
P/E ratio 2022 16,7x
Yield 2022 3,11%
Capitalization 256 B 273 B 273 B
EV / Sales 2022 4,16x
EV / Sales 2023 4,03x
Nbr of Employees 100 920
Free-Float 82,4%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 310,15 CHF
Average target price 374,13 CHF
Spread / Average Target 20,6%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Levi A. Garraway Chief Medical Officer
Pascale Schmidt Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-18.19%272 759
JOHNSON & JOHNSON-2.30%439 441
ELI LILLY AND COMPANY9.03%286 164
PFIZER, INC.-18.22%271 020
ABBVIE INC.4.93%251 211
NOVO NORDISK A/S6.37%248 905